				·	
	m BXA-621P V 1-94) U.S. DEPART Bureau REPORT OF REQUEST FOR RESTRICTIVE TRADE PRACTICE SINGLE TRANSACTION	of Ex	cport A	dministration	THIS SPACE FOR BXA USE 950363
	(For reporting requests described in Part 769 of the Export Administration Regulation NOTICE OF RIGHT TO PROTECT CERTAIN INFORMATION FROM DISCLOSURE				1200 5
					MONTH/YEAR L
The des	The Export Administration Act permits you to protect from public disclosure information regarding the quantity, description, and value of commodities or technical data supplied in Item 11 of this report and in any accompanying documents. If you do not claim this protection, all of the information in your report and in accompanying documents will be made available for public inspection and copying. You can obtain this protection by certifying, in Item 10 of the report, that disclosure of the information referred to above would place a United States company or individual involved in the report at a competitive disadvantage. If you make such a certification in Item 10, you may remove information regarding the quantity, description, and value of the commodities or technical data supplied by you from Item 11 of the inspection copy of the report form and from the public inspection copies of the accompanying documents.				6 9 RSN SUBSET]
doc					10 15 16 17
You					18 27.
to at					CLASS FILING TAG 80
and					This report required by law (50 U.S.C. App. §2407 (b)(2) P.L. 103-10;
disc	The withholding of this information will be honored by the Department unless the Secret disclosure of the information would not place a United States company or individual at a comp or that it would be contrary to the national interest to withhold the information.				15 C.F.R. Part 769. Failure to report can result both in criminal penalties, including fines or imprisonment, and administrative sanctions.
Instructions: 1. Complete all items that apply. 2. Assemble original report form and accompanying documents as a unit, and submit intact and unaltered. 3. Assemble and submit the duplicate copy of report form (marked Duplicate (Public Inspection Copy)) and additional copies of accompanying documents (marked with the legend "Public Inspection Copy.") 4. If you certify, in item 10, that the disclosure of the information specified there would cause competitive disadvantage, edit the "Public Inspection Copy" of the documents submitted to exclude the specified information and remove the bottom of the Duplicate "Public Inspection Copy" of the report form relating to Item 11.					
Public reporting for this collection of information is estimated to average one hour per request, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Office of Security and Management Support, Bureau of Export Administration, U.S. Department of Commerce, Washington, D.C. 20230; and to the Office of Management and Budget, Paperwork Reduction Project (0694-0012), Washington, D.C. 20503.					
1a.	Identify firm submitting this report: Name: Bristol-Myers Squibb Co. Specify X Expo	firm t	type:		any applicable box:
	Address: P.O. Box 4000		subn r □ Resu		sion of a previous report (attach two copies of the previously litted report)
					bmission of a deficient report returned by BXA (attach
	Telephone (609) 252-4600 Insur			1	letter that was returned with deficient report) ort on behalf of the person identified in Item 2
	Firm Identification No. (If known) 107533 — Othe	r 35		1	report on behalf of self and the person identified in Item 2
2.	If you are authorized to report and are reporting on behalf of another L person, identify that person (e.g., domestic subsidiary, controlled Fore subsidiary, exporter, beneficiary);		3.		ing firm, unless same as item 1a or 2:
	Name:				
	Address:				d ZIP:
	City, State, and ZIP:		İ	-	
	Country (if other than USA):			Firm Identifica	tion No. (If known):
	Type of firm: (see list in item 1a)			T IIII IGENLINGO	don'to. (ii kilomy.
	Firm Identification No. (If known):		┝		36-41 42
4.	Name of boycotting country from which request originated: Oman Name of country directing inclusion of request, if different from			Israe	try or countries against which request is directed:
	(a) above:43-	44			45-46
	Reporting firm's reference number (e.g., letter of credit, customer order, invoice): SQUH/178/98 71-	77	7.	Date firm rece	4/-52
8.	Specify type(s) of document conveying the request:				Submit two copies of
	☐ Request to carrier for blacklist certificate (submit two copies of blacklist certificate or transcript of request) ★ Bid invitation/tu				pepted contract/shipping instruction sach document and opportunity or relevant
	☐ Unwritten, not otherwise provided for (make transcript ☐ Ques	Inwritten, not otherwise provided for (make transcript			particular dollar value transaction) page in which the
	of request and submit copies) 53-54 □ Other written (specify)			pecify)	request appears
9.	Decision on request: (Check one)				
X Have not taken and will not take the action requested. □ Have taken or will take the action requested but in a modified					
	☐ Have taken or will take the action requested.				
	$\hfill \square$ Have taken or will take the action requested and claim it is			will inforn	report ultimate decision on the request at this time and in the Bureau of Export Administration of the decision within
	subject to a grace period (attach detailed explanation). 56-5				after decision is made. PD012444
Additional Information: The firm submitting this report may, if it so desires, state on a separate sheet any additional information relating to the request reported or the response to that request. This statement will constitute a part of the report and will be made available for public inspection and copying, subject to the right to protect certain confidential information from disclosure described in Item 10.					
10. Protection of Certain Information from Disclosure: (Check appropriate boxes and sign below)					
 1. XI (We) certify that disclosure to the public of the information regarding quantity, description, and value of the commodities or technical data contained in:					
Sig	(1-l)				il M. Vincent Date 1/29/99
-			•		

- 14. The Supplier must remove from the place of delivery the rejected item(s) within two weeks from the date of the advice of rejection (despatch date of the letter). The item(s) shall be left on the Supplier's responsibility during the said period. If the Supplier fails to remove the said item(s) within the above mentioned period a penalty of 0.2% per day shall be charged and recovered from any of the Supplier's future invoisor.
- 15. Tenders shall be checked for accuracy in computation and addition. In case there is an error in multiplication, the unit price or rate shall be considered as the correct entity and necessary amendments shall be made thereof.
- 16. Full details regarding packing, country of origin, period of delivery, mode of shipment (Air/Sea/Land) and storage conditions during shipment shall be mentioned in the offer.
- 17. All goods to be supplied as a part of this order must comply with the Israeli Boycott rules stipulated by the Royal Oman Police.
 - 13. All patterns, drawings, designs or specifications provided to the tenderer are to remain the University Hospital property, shall be returned on demand and treated as confidential.
 - 13. Samples or brochures/literatures against quoted items shall be submitted alongwith the tender otherwise the tender is likely to be rejected.
 - B. SPECIAL CONDITIONS FOR SUPPLY OF PHARMACEUTICALS, REAGENTS, CHEMICALS, X-RAY FILMS, DRESSINGS, DISPOSABLES ETC.
 - 1. All consignment of pharmaceuticals products must be accompanied by:
 - a. The method of analysis.

.(

- b. If the method of analysis specified that certain type of standards (authentic pure powder) are used during the Assay, then that standard is to be sent alongwith the consignment.
 - c. A Certificate showing that the product(s) is/are being used inthe country of origin under same conditions (name, ingredietnts, potency etc.)

d. Analysis certificate issued by y known laboratory in the country of ork duly attested by the Ministry of Health other concerned authorities.